BIOLASE, Inc.
BIOL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $49 | $48 | $39 | $23 |
| % Growth | 1.4% | 23.7% | 72% | – |
| Cost of Goods Sold | $32 | $33 | $23 | $17 |
| Gross Profit | $17 | $16 | $17 | $6 |
| % Margin | 34% | 32.8% | 42.2% | 27.1% |
| R&D Expenses | $6 | $7 | $6 | $4 |
| G&A Expenses | $10 | $12 | $11 | $10 |
| SG&A Expenses | $29 | $34 | $27 | $21 |
| Sales & Mktg Exp. | $18 | $22 | $15 | $11 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $35 | $41 | $33 | $25 |
| Operating Income | -$18 | -$25 | -$16 | -$19 |
| % Margin | -36.5% | -52.3% | -41.1% | -81.4% |
| Other Income/Exp. Net | -$3 | -$3 | $0 | $2 |
| Pre-Tax Income | -$21 | -$29 | -$16 | -$17 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21 | -$29 | -$16 | -$17 |
| % Margin | -42% | -59.1% | -41.2% | -73.9% |
| EPS | -16.14 | -413.19 | -273.41 | -688.19 |
| % Growth | 96.1% | -51.1% | 60.3% | – |
| EPS Diluted | -16.14 | -413.19 | -273.41 | -688.19 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $3 | $2 | $2 |
| Depreciation & Amortization | $3 | $0 | $0 | $0 |
| EBITDA | -$15 | -$25 | -$13 | -$14 |
| % Margin | -31.4% | -52.2% | -34.4% | -60.8% |